PT1476136E - Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco. - Google Patents

Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco.

Info

Publication number
PT1476136E
PT1476136E PT03700915T PT03700915T PT1476136E PT 1476136 E PT1476136 E PT 1476136E PT 03700915 T PT03700915 T PT 03700915T PT 03700915 T PT03700915 T PT 03700915T PT 1476136 E PT1476136 E PT 1476136E
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
salt
granules
weight
piperidinyl
Prior art date
Application number
PT03700915T
Other languages
English (en)
Inventor
Philip C Buxton
Sharon E Groves
Thomson Seona
Dirk M J Van Schie
Kenneth T Yeates
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203528A external-priority patent/GB0203528D0/en
Priority claimed from GB0203526A external-priority patent/GB0203526D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PT1476136E publication Critical patent/PT1476136E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT03700915T 2002-02-14 2003-01-22 Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco. PT1476136E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0203528A GB0203528D0 (en) 2002-02-14 2002-02-14 Process and composition
GB0203526A GB0203526D0 (en) 2002-02-14 2002-02-14 Process and composition

Publications (1)

Publication Number Publication Date
PT1476136E true PT1476136E (pt) 2006-10-31

Family

ID=27736214

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03700915T PT1476136E (pt) 2002-02-14 2003-01-22 Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco.

Country Status (22)

Country Link
US (1) US20050075335A1 (pt)
EP (1) EP1476136B1 (pt)
JP (1) JP2005523276A (pt)
KR (1) KR100967782B1 (pt)
AT (1) ATE329581T1 (pt)
AU (1) AU2003202058B2 (pt)
BR (1) BR0307666A (pt)
CA (1) CA2475659A1 (pt)
CO (1) CO5611095A2 (pt)
CY (1) CY1106148T1 (pt)
DE (1) DE60306120T2 (pt)
DK (1) DK1476136T3 (pt)
ES (1) ES2263949T3 (pt)
HK (1) HK1072359A1 (pt)
IS (1) IS2393B (pt)
MX (1) MXPA04007857A (pt)
NO (1) NO20043834L (pt)
NZ (1) NZ534333A (pt)
PL (1) PL206544B1 (pt)
PT (1) PT1476136E (pt)
RU (1) RU2329789C2 (pt)
WO (1) WO2003068193A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
KR20090007622A (ko) * 2006-05-04 2009-01-19 노파르티스 아게 약학 조성물을 제조하기 위한 가열 롤러 압축 방법
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
ES2449074T3 (es) * 2007-06-22 2014-03-18 Bristol-Myers Squibb Holdings Ireland Composiciones en forma de comprimidos que contienen atazanavir
RU2471356C2 (ru) * 2007-07-31 2013-01-10 Карджилл, Инкорпорейтед Декстроза для прямого прессования
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
TWI461213B (zh) 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
RU2564922C2 (ru) * 2011-04-19 2015-10-10 Григорий Яковлевич ЛЕГИН Композиция для изготовления спороцидных композиций надуксусной кислоты, способ (варианты) и набор для его осуществления
US9606054B2 (en) 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
US9417181B2 (en) 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
CN104945303B (zh) * 2015-06-15 2017-09-29 浙江工业大学 3‑烯基吲哚类化合物的制备方法
PE20221838A1 (es) * 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
KR102499289B1 (ko) * 2022-04-15 2023-02-14 주식회사 비에스앤코 가루치약의 제조방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
AP401A (en) * 1992-03-12 1995-08-29 Smithkline Beecham Plc Condensed indole derivatives as 5H4-receptor antagonists.
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
CA2418904A1 (en) * 2000-08-07 2002-02-14 Laboratoire Glaxosmithkline S.A.S. Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
EP1313481B1 (en) * 2000-08-08 2007-09-26 Smithkline Beecham Plc Pharmaceutical composition comprising condensed indole compound
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6666298B2 (en) * 2001-11-21 2003-12-23 John Volkman Hanging scaffold support

Also Published As

Publication number Publication date
WO2003068193A1 (en) 2003-08-21
AU2003202058A1 (en) 2003-09-04
RU2004127450A (ru) 2005-04-10
EP1476136B1 (en) 2006-06-14
CO5611095A2 (es) 2006-02-28
JP2005523276A (ja) 2005-08-04
PL371963A1 (en) 2005-07-11
MXPA04007857A (es) 2004-10-15
IS2393B (is) 2008-08-15
US20050075335A1 (en) 2005-04-07
DE60306120D1 (de) 2006-07-27
ES2263949T3 (es) 2006-12-16
DK1476136T3 (da) 2006-10-09
CY1106148T1 (el) 2011-06-08
AU2003202058B2 (en) 2009-05-28
NZ534333A (en) 2006-05-26
RU2329789C2 (ru) 2008-07-27
KR100967782B1 (ko) 2010-07-05
CA2475659A1 (en) 2003-08-21
BR0307666A (pt) 2005-01-11
ATE329581T1 (de) 2006-07-15
DE60306120T2 (de) 2006-11-09
IS7398A (is) 2004-08-12
NO20043834L (no) 2004-10-26
EP1476136A1 (en) 2004-11-17
KR20040097996A (ko) 2004-11-18
PL206544B1 (pl) 2010-08-31
HK1072359A1 (en) 2005-08-26

Similar Documents

Publication Publication Date Title
HK1072359A1 (en) Pharmaceutical composition comprising N-((1-N-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2H-(1,3)oxazino(3,2-A)indole-10carboxamide or salt and process for preparing thereof comprising dry granulation
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
TR199802698T2 (xx) Valsartan�n kat� oral doz formlar�.
RU2008143545A (ru) Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
MXPA04005105A (es) Formulaciones de acitromicina directamente compresibles.
EA200100024A1 (ru) Состав таблетки с делавирдином
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
EA200500388A1 (ru) Способ получения сухих порошковых композиций для ингаляции
NO20051896L (no) Farmasoytisk sammensetning som fast doseringsform samt fremgangsmate for fremstilling derav
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
NO20055536L (no) Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon
NZ510583A (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
MY118569A (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
DE60233552D1 (de) Fenofibrattabletten
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
ES2172481A1 (es) Composicion farmaceutica que contiene citalopram.
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
UA89408C2 (ru) Твердая фармацевтическая композиция пролонгированного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
MXPA02009210A (es) Modificacion amorfa de torasemida.
PE20040915A1 (es) Complejos de e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil)acetamida, su procedimiento de preparacion y composiciones farmaceuticas
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
EA200600932A1 (ru) Таблетки циталопрама гидробромида
BRPI0414319A (pt) agentes antibacterianos de quinolona
HRP20030957A2 (en) USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS